Evidence map›Paper›PMID 39042682›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology.

Jung-Hyun Choi, Laura Marsal-García, Eve Peraldi, Caleb Walters, Ziying Huang, Ilse Gantois, Nahum Sonenberg

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jung-Hyun Choi *Department of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.ORCID 0000-0002-8992-4992
Laura Marsal-García *Department of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.ORCID 0000-0002-6337-1656
Eve PeraldiDepartment of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.ORCID 0000-0002-5417-2145
Caleb WaltersDepartment of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.
Ziying HuangDepartment of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.
Ilse GantoisDepartment of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.ORCID 0000-0002-5421-2581
Nahum SonenbergDepartment of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.ORCID 0000-0002-4707-8759

Funding

Canadian Government | Canadian Institutes of Health Research (CIHR) FDN-148423FRAXA Research Foundation (FRF) N/ANational Research Foundation of Korea (NRF) 2020R1A6A3A03040141
6 · The paper itself

Abstract

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder engendered by transcriptional silencing of the fragile X messenger ribonucleoprotein 1 (

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeMetforminAnimalsDisease Models, AnimalMaleMechanistic Target of Rapamycin Complex 1MiceMice, KnockoutSignal TransductionFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1Mechanistic Target of Rapamycin Complex 1Metforminautism spectrum disorderFmr1 KO mouse modelfragile X syndromemetforminmTORC1 and ERK signaling pathways

Identifiers

PMID39042682
PMCPMC11295030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.